Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 60

1.

Safety of BTZ retreatment for patients with low-grade peripheral neuropathy during the initial treatment.

Vidisheva AP, Wang J, Spektor TM, Bitran JD, Lutzky J, Tabbara IA, Ye JZ, Ailawadhi S, Stampleman LV, Steis RG, Moezi MM, Swift RA, Maluso TM, Udd KA, Eshaghian S, Nassir Y, Berenson JR.

Support Care Cancer. 2017 Apr 28. doi: 10.1007/s00520-017-3732-6. [Epub ahead of print]

PMID:
28455546
2.

Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer.

Agnelli G, George DJ, Kakkar AK, Fisher W, Lassen MR, Mismetti P, Mouret P, Chaudhari U, Lawson F, Turpie AG; SAVE-ONCO Investigators.

N Engl J Med. 2012 Feb 16;366(7):601-9. doi: 10.1056/NEJMoa1108898.

3.

Cetuximab in combination with carboplatin and docetaxel for patients with metastatic or advanced-stage nonsmall cell lung cancer: a multicenter phase 2 study.

Belani CP, Schreeder MT, Steis RG, Guidice RA, Marsland TA, Butler EH, Ramalingam SS.

Cancer. 2008 Nov 1;113(9):2512-7. doi: 10.1002/cncr.23902.

4.

Bone marrow transplantation: cancer therapy comes of age.

Owen P, Connaghan DG, Holland HK, Steis RG.

J Med Assoc Ga. 1998 Apr;87(2):145-6, 148. No abstract available.

PMID:
16259263
5.

Weekly paclitaxel, estramustine phosphate, and oral etoposide in the treatment of hormone-refractory prostate carcinoma: results of a Minnie Pearl Cancer Research Network phase II trial.

Meluch AA, Greco FA, Morrissey LH, Raefsky EL, Steis RG, Butts JA, Hainsworth JD; Minnie Pearl Cancer Research Network.

Cancer. 2003 Nov 15;98(10):2192-8.

6.

Paclitaxel and gemcitabine chemotherapy for advanced transitional-cell carcinoma of the urothelial tract: a phase II trial of the Minnie pearl cancer research network.

Meluch AA, Greco FA, Burris HA 3rd, O'Rourke T, Ortega G, Steis RG, Morrissey LH, Johnson V, Hainsworth JD.

J Clin Oncol. 2001 Jun 15;19(12):3018-24.

PMID:
11408496
7.

A phase II study of carboplatin, cisplatin, interferon-alpha, and tamoxifen for patients with metastatic melanoma.

Gause BL, Sharfman WH, Janik JE, Curti BD, Steis RG, Urba WJ, Smith JW 2nd, Alvord WG, Longo DL.

Cancer Invest. 1998;16(6):374-80.

PMID:
9679527
8.

A phase I randomized study of subcutaneous adjuvant IL-2 in combination with an autologous tumor vaccine in patients with advanced renal cell carcinoma.

Fenton RG, Steis RG, Madara K, Zea AH, Ochoa AC, Janik JE, Smith JW 2nd, Gause BL, Sharfman WH, Urba WJ, Hanna MG, DeJager RL, Coyne MX, Crouch RD, Gray P, Beveridge J, Creekmore SP, Holmlund J, Curti BD, Sznol M, Longo DL.

J Immunother Emphasis Tumor Immunol. 1996 Sep;19(5):364-74.

PMID:
8941876
9.

Phase I study of subcutaneously administered interleukin-2 in combination with interferon alfa-2a in patients with advanced cancer.

Gause BL, Sznol M, Kopp WC, Janik JE, Smith JW 2nd, Steis RG, Urba WJ, Sharfman W, Fenton RG, Creekmore SP, Holmlund J, Conlon KC, VanderMolen LA, Longo DL.

J Clin Oncol. 1996 Aug;14(8):2234-41.

PMID:
8708712
10.

Phase II trial of interleukin 1 alpha and indomethacin in treatment of metastatic melanoma.

Janik JE, Miller LL, Longo DL, Powers GC, Urba WJ, Kopp WC, Gause BL, Curti BD, Fenton RG, Oppenheim JJ, Conlon KC, Holmlund JT, Sznol M, Sharfman WH, Steis RG, Creekmore SP, Alvord WG, Beauchamp AE, Smith JW 2nd.

J Natl Cancer Inst. 1996 Jan 3;88(1):44-9.

PMID:
8847725
11.

Clinical relevance of recombinant interferon-alpha 2a antibodies in patients with hairy cell leukemia.

Steis RG, Longo DL.

J Interferon Res. 1994 Aug;14(4):207-9. No abstract available.

PMID:
7822877
12.

T-cell receptor gene rearrangement in T-cell large granular leukocyte leukemia: preferential V alpha but diverse J alpha usage in one of five patients.

Kasten-Sport├Ęs C, Zaknoen S, Steis RG, Chan WC, Winton EF, Waldmann TA.

Blood. 1994 Feb 1;83(3):767-75.

13.

Total-body irradiation and autologous bone marrow transplant in the treatment of high-risk Ewing's sarcoma and rhabdomyosarcoma.

Horowitz ME, Kinsella TJ, Wexler LH, Belasco J, Triche T, Tsokos M, Steinberg SM, McClure L, Longo DL, Steis RG, et al.

J Clin Oncol. 1993 Oct;11(10):1911-8.

PMID:
8410118
14.

Immunomodulatory effects of interferon-gamma in patients with metastatic malignant melanoma.

Kopp WC, Smith JW 2nd, Ewel CH, Alvord WG, Main C, Guyre PM, Steis RG, Longo DL, Urba WJ.

J Immunother Emphasis Tumor Immunol. 1993 Apr;13(3):181-90.

PMID:
8471592
15.

Dose-related immunologic effects of levamisole in patients with cancer.

Janik J, Kopp WC, Smith JW 2nd, Longo DL, Alvord WG, Sharfman WH, Fenton RG, Sznol M, Steis RG, Creekmore SP, et al.

J Clin Oncol. 1993 Jan;11(1):125-35.

PMID:
8418223
16.

The toxic and hematologic effects of interleukin-1 alpha administered in a phase I trial to patients with advanced malignancies.

Smith JW 2nd, Urba WJ, Curti BD, Elwood LJ, Steis RG, Janik JE, Sharfman WH, Miller LL, Fenton RG, Conlon KC, et al.

J Clin Oncol. 1992 Jul;10(7):1141-52.

PMID:
1607919
17.

Intensive therapy with cisplatin, interleukin-2 and interferon-alpha-2a in patients with metastatic melanoma. A phase II Study.

Sznol M, Steis RG, Smith JW 2nd, Janik JE, Sharfman WH, Urba WJ, Fenton RG, Creekmore SP, Beveridge J, Longo DL.

Online J Curr Clin Trials. 1992 Jul 1;Doc No 9:[3841 words; 32 paragraphs].

PMID:
1343617
18.

Pilot study of interleukin-2 and lymphokine-activated killer cells combined with immunomodulatory doses of chemotherapy and sequenced with interferon alfa-2a in patients with metastatic melanoma and renal cell carcinoma.

Sznol M, Clark JW, Smith JW 2nd, Steis RG, Urba WJ, Rubinstein LV, VanderMolen LA, Janik J, Sharfman WH, Fenton RG, et al.

J Natl Cancer Inst. 1992 Jun 17;84(12):929-37.

PMID:
1629914
19.

Polyinosinic-polycytidylic acid complexed with poly-L-lysine and carboxymethylcellulose in combination with interleukin 2 in patients with cancer: clinical and immunological effects.

Ewel CH, Urba WJ, Kopp WC, Smith JW 2nd, Steis RG, Rossio JL, Longo DL, Jones MJ, Alvord WG, Pinsky CM, et al.

Cancer Res. 1992 Jun 1;52(11):3005-10.

20.

Anti-CD3 monoclonal antibody treatment of patients with CD3-negative tumors: a phase IA/B study.

Urba WJ, Ewel C, Kopp W, Smith JW 2nd, Steis RG, Ashwell JD, Creekmore SP, Rossio J, Sznol M, Sharfman W, et al.

Cancer Res. 1992 May 1;52(9):2394-401.

Supplemental Content

Loading ...
Support Center